Skip to main content
. 2017 May 24;8(46):81285–81294. doi: 10.18632/oncotarget.18150

Table 2. Acute rejection rate in different CYP3A5 genotype.

Characteristics FK506 CsA
GG AA/AG GG AA/AG
Patient, n (AA/AG) 65 58 (11/47) 52 43 (9/34)
Acute rejection, n(%) 4(6.15%)a 8(13.79%) 10(19.23%) 6(13.95%)
Acute rejection based on type of Immunosuppressive drugs, n(%) 12(9.76%) 16(16.84%)
Total acute rejection, n(%) 28(12.84%)

a : p < 0.05 vs CYP3A5*GG with CsA treatment.